Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1/1b, Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Next Previous
X
Search
Trial Profile

An Open-Label, Phase 1/1b, Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ORIC-944 (Primary)
  • Indications Neuroendocrine carcinoma; Prostate cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors ORIC Pharmaceuticals

    • Most Recent Events

    • 08 Jan 2024 Initial Phase 1b monotherapy data (data cut off: 10 Dec 2023) for ORIC-944 published in the ORIC Pharmaceuticals Media Release
    • 26 Jun 2023 According to an ORIC Pharmaceuticals media release, the company will report initial safety, PK/PD, and preliminary antitumor activity data from ongoing single agent Phase 1b study in patients with prostate cancer in the first quarter of 2024.
    • 18 Apr 2023 According to an ORIC Pharmaceuticals media release, an abstract of Preclinical data provided insights into the comprehensive biomarker strategy for this study presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top